OBJECTIVE: The objective of this study was to assess craving and mood related to opioid and cocaine use among asymptomatic hepatitis C virus (HCV)+ and HCV- methadone patients who have not started antiviral treatment. METHODS: In this 28-week prospective ecological momentary assessment (EMA) study, 114 methadone-maintained, heroin- and cocaine-abusing individuals reported from the field in real time on their mood, craving, exposure to drug-use triggers, and drug use via handheld computers. RESULTS: Sixty-one percent were HCV+; none were overtly symptomatic or receiving HCV treatment. HCV status was not associated with age, sex, race, or past-30-day or lifetime heroin or cocaine use. In event-contingent EMA entries, HCV+ individuals more often attributed use to having been bored, worried, or sad; feeling uncomfortable; or others being critical of them compared with HCV- participants. In randomly prompted EMA entries, HCV+ participants reported significantly more exposure to drug-use triggers, including handling ≥$10, seeing cocaine or heroin, seeing someone being offered/use cocaine or heroin, being tempted to use cocaine, and wanting to see what would happen if they used just a little cocaine or heroin. CONCLUSIONS: HCV+ individuals experienced more negative moods and more often cited these negative moods as causes for drug use. HCV+ individuals reported greater exposure to environmental drug-use triggers, but they did not more frequently cite these as causes for drug use. The EMA data reported here suggest that HCV+ intravenous drug users may experience more labile mood and more reactivity to mood than HCV- intravenous drug users. The reason for the difference is not clear, but HCV status may be relevant to tailoring of treatment.
OBJECTIVE: The objective of this study was to assess craving and mood related to opioid and cocaine use among asymptomatic hepatitis C virus (HCV)+ and HCV- methadonepatients who have not started antiviral treatment. METHODS: In this 28-week prospective ecological momentary assessment (EMA) study, 114 methadone-maintained, heroin- and cocaine-abusing individuals reported from the field in real time on their mood, craving, exposure to drug-use triggers, and drug use via handheld computers. RESULTS: Sixty-one percent were HCV+; none were overtly symptomatic or receiving HCV treatment. HCV status was not associated with age, sex, race, or past-30-day or lifetime heroin or cocaine use. In event-contingent EMA entries, HCV+ individuals more often attributed use to having been bored, worried, or sad; feeling uncomfortable; or others being critical of them compared with HCV- participants. In randomly prompted EMA entries, HCV+ participants reported significantly more exposure to drug-use triggers, including handling ≥$10, seeing cocaine or heroin, seeing someone being offered/use cocaine or heroin, being tempted to use cocaine, and wanting to see what would happen if they used just a little cocaine or heroin. CONCLUSIONS:HCV+ individuals experienced more negative moods and more often cited these negative moods as causes for drug use. HCV+ individuals reported greater exposure to environmental drug-use triggers, but they did not more frequently cite these as causes for drug use. The EMA data reported here suggest that HCV+ intravenous drug users may experience more labile mood and more reactivity to mood than HCV- intravenous drug users. The reason for the difference is not clear, but HCV status may be relevant to tailoring of treatment.
Authors: Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt Journal: Lancet Date: 2011-07-27 Impact factor: 79.321
Authors: John Orwat; Richard Saitz; Christopher P Tompkins; Debbie M Cheng; Michael P Dentato; Jeffrey H Samet Journal: J Subst Abuse Treat Date: 2011-06-22
Authors: Marilyn Huckans; Adriana Seelye; Jonathan Woodhouse; Tiffany Parcel; Lisa Mull; Daniel Schwartz; Alex Mitchell; David Lahna; Amy Johnson; Jennifer Loftis; Steven Paul Woods; Suzanne H Mitchell; William Hoffman Journal: J Clin Exp Neuropsychol Date: 2010-08-06 Impact factor: 2.475
Authors: P Fabris; G Tositti; M T Giordani; V Baldo; A Grasso; E Pignattari; S Canton; S Rossato; A Floreani Journal: Aliment Pharmacol Ther Date: 2006-04-15 Impact factor: 8.171
Authors: William J Kowalczyk; Jeremiah W Bertz; Landhing M Moran; Karran A Phillips; Udi E Ghitza; David H Epstein; Kenzie L Preston Journal: J Addict Med Date: 2017 Nov/Dec Impact factor: 3.702
Authors: Benjamin F Henwood; Brian Redline; Eldin Dzubur; Danielle R Madden; Harmony Rhoades; Genevieve F Dunton; Eric Rice; Sara Semborski; Qu Tang; Stephen S Intille Journal: JMIR Res Protoc Date: 2019-01-10